Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes
- 15 September 2011
- journal article
- Published by Elsevier BV in International Journal of Pharmaceutics
- Vol. 416 (1), 296-299
- https://doi.org/10.1016/j.ijpharm.2011.05.082
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implicationsInternational Immunopharmacology, 2003
- The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdvances in Enzyme Regulation, 2001
- In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.2001
- The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoproteinBritish Journal of Pharmacology, 1999
- Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivativesBioorganic & Medicinal Chemistry Letters, 1999
- Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.British Journal of Cancer, 1998
- P-glycoprotein—A mediator of multidrug resistance in tumour cellsEuropean Journal of Cancer, 1996
- In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.1993
- In vitro andin vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivativeInvestigational New Drugs, 1992
- Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivativeExperimental Cell Research, 1991